Accelerate Your Oncology Research

Tumor • Microenvironment • Immune Response

Cancer is a complex disease characterized by interactions between the tumor, microenvironment, and immune system. A broader and deeper understanding of the biology and signaling pathways that lead to cancer enables scientists to better identify, characterize, and target biomarkers that can ultimately be translated into clinical applications. Advances in molecular tools now enable a multiomic, holistic view of cancer that rapidly advances the understanding of how tumors develop, evade the immune system, and progress.


Cancer is a constellation of highly heterogenous diseases that share a common origin in mutations that drive key cellular functions like proliferation and cell death. Each cell in a tumor can bear its own genomic alterations and expression programs. Tissue-based and microenvironmental pressures add their own unique features to tumor pathology. Patients may also respond differently to treatment due to their own genetic makeup and microbiome, creating challenges for translating insights from model organisms to humans. Finally, the immune response adds an additional axis of complexity that adds to the challenge of cancer research and treatment.

Cancer is not just one disease

There are over 100 types of cancer

Tumor microenvironment impacts immune response

There are many influences to cancer growth and treatment

Not all patients respond to treatments

Biomarkers & signatures needed to understand who responds

Your Trusted Partner in Cancer Research

NanoString has been developing cancer research tools for over 20 years and believes in partnering with scientists to advance their research. We offer integrated, multiomic research tools for every stage of the translational research continuum. Whether you’re profiling the expression of 800+ genes with the nCounter® Analysis System, performing spatial profiling with the GeoMx® Digital Spatial Profiler (DSP), or getting single cell and subcellular spatial multiomics data with the CosMx™ Spatial Molecular Imager (SMI), we are here to partner with you every step of the way.

Three Platforms. Unlimited Potential.

Overcome cancer heterogeneity with a suite of translational tools and solutions that empower you to get actionable insights faster at any scale, from single cells to multi-cellular molecular compartments in the tumor microenvironment.

nCounter Pro Analysis System

Analysis System

  • Discover predictive and prognostic biomarkers  
  • Evaluate mechanisms of treatment response  
  • Monitor disease biomarkers in clinical trials  
  • Stratify patients using validated TIS, PAM50 and LST gene signatures 
GeoMx Digital Spatial Profiler

Digital Spatial Profiler

  • Understand tumor heterogeneity
  • Understand impact of the tumor microenvironment on the immune response
  • Measure treatment response in clinical trials
  • Characterize the microenvironment along the tumor invasive margin
  • Discover and validate spatial biomarkers
CosMx Spatial Molecular Imager

Spatial Molecular Imager

  • Identify cellular neighborhoods that reveal tumor heterogeneity
  • Reveal functional changes within a tumor at single cell resolution
  • Characterize up to 100 oncology-specific ligand receptor pairs (including major drug targets) between interacting cells

Spotlight on Success

Related Resources

View All Resources
Brochure/eBook Oncology Solutions – Brochure
Blog Post From an Egyptian Papyrus to the Hallmarks of Cancer: A Journey through the Development of Knowledge in Oncology Research
Blog Post Going Beyond PDL-1. Q&A with Dr. Nina Radosevic- Robin, MD.
Blog Post How the Field of Immuno-Oncology is Changing Fast
App Note/Tech Note Ultra-High-Plex Spatial Proteogenomics of FFPE Tissue Sections

Case Studies and Testimonials

Customer Testimonials
Case Studies
Customer Testimonials

Oncology Customer Testimonials

Case Studies

Oncology Case Studies


View All Publications

SITC 2023: Gene signature predicts autoimmune toxicity in patients with metastatic melanoma

Expression patterns of microRNAs and associated target genes in ulcerated primary cutaneous melanoma

Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial

B7 homolog 3 (B7-H3; CD276), a tumor-associated antigen and possible immune checkpoint, is highly expressed in prostate cancer (PCa) and is associated with early recurrence and metastasis. Enoblituzumab is a humanized, Fc-engineered, B7-H3-targeting antibody that mediates antibody-dependent cellular cytotoxicity.

Digital spatial profiling of intraductal papillary mucinous neoplasms: Toward a molecular framework for risk stratification

The histopathologic heterogeneity of intraductal papillary mucinous neoplasms (IPMN) complicates the prediction of pancreatic ductal adenocarcinoma (PDAC) risk. Intratumoral regions of pancreaticobiliary (PB), intestinal (INT), and gastric foveolar (GF) epithelium may occur with either low-grade dysplasia (LGD) or high-grade dysplasia (HGD).

Single-cell heterogeneity of EGFR and CDK4 co-amplification is linked to immune infiltration in glioblastoma

Glioblastoma (GBM) is the most aggressive brain tumor, with a median survival of ∼15 months. Targeted approaches have not been successful in this tumor type due to the large extent of intratumor heterogeneity.


Contact Us

Have questions or simply want to learn more?

Contact our helpful experts and we’ll be in touch soon.

Contact Us